GlassScriptPhysician profile
Shefali N Patel
NPI 1427146596
$4,627.25
in general payments reported to CMS, 2019-2025
19 companies · $651 in 2025
The $651 reported for 2025 was more than what 80% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $114 · 2021: $521 · 2022: $659 · 2023: $1,214 · 2024: $419 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.96 |
| Education | $401.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $1,895.20 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $545.50 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $481.11 | 2021-2025 | |
| Abbvie INC. | $380.04 | 2019-2023 | |
| Hologic Sales and Service, LLC | $264.02 | 2021-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Millicent US INC | $201.11 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Evofem Biosciences, INC. | $166.09 | 2021-2024 | Phexxi |
| Therapeuticsmd, INC. | $151.90 | 2019-2021 | |
| Pfizer INC. | $115.33 | 2020-2024 | |
| Avion Pharmaceuticals | $111.49 | 2021-2023 | Balcoltra |
| Myovant Sciences INC. | $83.29 | 2022 | |
| Agile Therapeutics, INC. | $55.84 | 2021-2023 | Twirla |
| Sumitomo Pharma America, INC. | $43.01 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $31.30 | 2020-2025 | |
| Merz North America, INC. | $31.18 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $23.76 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.57 | 2023 | Quviviq |
| Allergan, INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shefali Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.